

KING PHARMACEUTICALS INC

Form 8-K

March 16, 2004

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 12, 2004

**King Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Tennessee**  
(State or other jurisdiction  
of incorporation)

**0 24425**  
(Commission  
File Number)

**54-1684963**  
(IRS Employer  
Identification Number)

**501 Fifth Street, Bristol, Tennessee**  
(Address of principal executive offices)

**37620**  
(Zip Code)

Registrant's telephone number, including area code: **423-989-8000**

**Not Applicable**

(Former name or former address, if changed since last report)

---

---

**Item 5. Other Events**

King Pharmaceuticals, Inc., a Tennessee corporation, announced on March 12, 2004 that on March 9, 2004, it received a copy of a letter from the U.S. Food and Drug Administration ( FDA ) to all Abbreviated New Drug Application ( ANDA ) applicants for a generic equivalent to King s approved product Skelaxin® 400 mg (metaxalone). The letter stated that ANDA applicants may delete the use listed in the FDA s publication entitled Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book ) for U.S. Patent No. 6,407,128 from their product labeling. Skelaxin® is a muscle relaxant, indicated for the relief of discomforts associated with acute, painful musculoskeletal conditions. On March 12, 2004, King issued a press release regarding the announcement.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits**

(c) Exhibits.

The following exhibits are filed pursuant to Item 601 of Regulation S-K:

**Exhibits:**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release of King Pharmaceuticals, Inc. dated March 12, 2004.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 15, 2004

KING PHARMACEUTICALS, INC.

By: /s/ James R. Lattanzi

---

James R. Lattanzi  
Chief Financial Officer

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release of King Pharmaceuticals, Inc. dated March 12, 2004.